Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin

Engelmann, Simon Udo and Pickl, Christoph and Haas, Maximilian and Kasparbauer, Felix and Rinderknecht, Emily and Kälble, Sebastian and van Rhijn, Bas W. G. and Siska, Peter J. and Decking, Sonja-Maria and Renner, Kathrin and Pichler, Renate and Burger, Maximilian and Guzvic, Miodrag and Mayr, Roman (2025) Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin. CLINICAL GENITOURINARY CANCER, 23 (4): 102378. ISSN 1558-7673, 1938-0682

Full text not available from this repository. (Request a copy)

Abstract

Interleukin-6 (IL-6) is associated with poor outcomes in bladder cancer (BC) patients, including worse overall survival (OS) and cancer-specific survival (CSS). This study analyzed serum IL-6 levels in 179 BC patients undergoing radical cystectomy and IL-6 concentrations in tumor tissue from 20 additional patients. High serum IL-6 was an independent predictor of OS and CSS, and higher levels were linked to advanced tumor stage, lymph node metastasis, and larger tumor size. Tumor tissue IL-6 was significantly elevated in muscle-invasive BC compared to early-stage tumors. These findings underscore the prognostic potential of IL-6 and its relevance in BC theranostics.<br /> Background: Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. Objective of this study is to analyze the prognostic value of IL-6 in BC patients and to investigate its concentration in tumor tissue. Methods: In this single center prospective observational study, preoperative serum samples of 179 BC patients undergoing radical cystectomy were collected between September 2019 and September 2022. Tumor-tissue of additional 20 patients was collected during transurethral resection or radical cystectomy for investigation of IL-6 in tumor tissue supernatant. IL-6 concentration was measured by ELISA. Results: Median serum IL-6 concentration was 5.4 pg/mL. High serum IL-6 was an independent predictor of OS (HR 1.95; 95% CI, 1.07-3.55; P = .03) and CSS (HR 2.31; 95% CI, 1.14-4.68; P = .02) in multivariate Cox regression analyses. Patients with advanced tumor stage, lymph node metastasis, and larger tumor size had significantly higher preoperative serum IL-6 concentration (all P < .01). In tumor tissue supernatant, IL-6 concentration was higher in muscle-invasive BC, with a median of 715.4 pg/mL, as opposed to 20.7 pg/mL in pTa tumor stage ( P < .01). Conclusions: Serum IL-6 is a strong predictor of poor survival rates and adverse pathologic features in BC patients. IL-6 concentrations in tumor tissue supernatant correlate with tumor stage. The role of IL-6 in theranostics of bladder cancer deserves more attention.

Item Type: Article
Uncontrolled Keywords: INTERLEUKIN-6; RECEPTOR; Biomarker; Tumor microenvironment; Urothelial cancer; Immunology; Interleukin
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde
Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Medicine > Lehrstuhl für Urologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 15 Oct 2026 07:47
Last Modified: 15 Oct 2026 07:47
URI: https://pred.uni-regensburg.de/id/eprint/66292

Actions (login required)

View Item View Item